Compare Compass Inc. Class A Common Stock (COMP) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Compass Inc. Class A Common Stock vs Sana Biotechnology Inc — how do they compare? Compass Inc. Class A Common Stock trades at $9.52 (market cap $7.05B), while Sana Biotechnology Inc trades at $2.73 (market cap $812.76M). The key difference: Compass Inc. Class A Common Stock is far larger — about 8.7× Sana Biotechnology Inc's market cap, and Compass Inc. Class A Common Stock is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Compass Inc. Class A Common Stock for 0 Days and Sana Biotechnology Inc for 23 Days on average.
| COMP | SANA | |
|---|---|---|
Market Cap | $7.05B | $812.76M |
Volume | 15,310,192 | 4,314,200 |
Sector | Real Estate | Health |
52-Week High | $13.58 | $5.92 |
52-Week Low | $6.68 | $2.68 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $10.47B | $726.01M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $2.72, down 1.09% today, showing bearish technical signals with negative moving averages but oversold RSI readings. The company reported no revenue in 2025 with substantial losses (-$244.17M net income) and negative cash flow (-$55.33M), though analyst sentiment remains positive with 82% buy ratings. Recent investor conference presentations highlight ongoing clinical development activities.
While analyst consensus is bullish with a $9.50 price target (Defense World, July 30, 2026), SANA faces significant fundamental challenges including negative profitability metrics and cash burn. Investment appeal hinges on clinical pipeline success, with risks including execution challenges and the pre-revenue biotech business model requiring continued financing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Compass Inc. Class A Common Stock
Compass is a technology-enabled residential real estate company. Its platform provides agents with tools for customer relationships, marketing, client service, and transactions, alongside brokerage, title, escrow, and mortgage services.
Read more on COMP →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
